Incyte (INCY) Tops Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Incyte (INCY): Tumor Removal Drives Estimate Cut - UBS
February 12, 2016 8:57 AM ESTUBS analyst, Matthew Roden, looked through a good quarter for Incyte (NASDAQ: INCY) to the importance of pipeline growth. He adjusted his model to remove the contribution of Jakafi in solid tumors which led him to cut his PT to $88 from $110. No change to the Buy rating though as the new PT implies 35% upside.
Although 4Q operations beat cleanly on the top/bottom lines, 2016 opex guidance and in particular the failure of Jakafi in solid tumors caused a PT cut to $88 (from $110) as solid tumors (and '110) are removed from the model. Risk-adjusted... More
Incyte (INCY) to Halt Ruxolitinib + Capecitabine Phase 3 in Advanced or Metastatic Pancreatic Cancer
February 11, 2016 6:46 AM ESTIncyte Corporation (Nasdaq: INCY) announced its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer. The decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation.
Following these results, and the... More
